Institut Paoli Calmettes — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

5 Recruiting

3 Completed trials

2 Countries active

12 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase II: 5 Phase I/II: 1 Phase I: 2 Phase I (Other): 1

Oversight events:

6 temporary halts across 2 trials

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Myelodysplastic syndrome 2 Acute biphenotypic leukaemia 1 HER2 negative breast cancer 1 Acute myeloid leukaemia recurrent 1 Acute lymphocytic leukaemia refractory 1 Acute lymphocytic leukaemia recurrent 1

Top IMPs

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN 2 AZACITIDINE 1 BUSULFAN 1 CYCLOPHOSPHAMIDE 1 DASATINIB 1 EPIRUBICIN HYDROCHLORIDE 1 FLUDARABINE PHOSPHATE 1 PACLITAXEL 1 PEMBROLIZUMAB 1 TUVUSERTIB 1 VENETOCLAX 1

All trials

9 total

MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors… Recruiting

2023-507485-10-00 Phase I/II 1 country TUVUSERTIB
STOP VEN-IPC 2024-001 DE-ESCALATION STUDY EVALUATING VENETOCLAX AND AZACITIDINE DISCONTINUATION IN AML RESPONDING PATIENTS Recruiting

2024-514112-28-00 Phase II 1 country AZACITIDINE; VENETOCLAX
CASPER-ATG-IPC 2023-015 : Reinforced prophylaxis of GVH in elderly patients with haematological malignancies receiving haploidentical alloge… Recruiting

2023-506648-18-00 Phase II 1 country RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i… Recruiting

2024-514899-41-00 Phase II 1 country CYCLOPHOSPHAMIDE; EPIRUBICIN HYDROCHLORIDE; PACLITAXEL; PEMBROLIZUMAB
CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY AC… Recruiting

2024-515737-14-00 Phase I (Other) 1 country
FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS Ended

2023-504605-36-00 Phase I 2 countries
VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy efficacy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE Halted

2023-505846-24-00 Phase II 1 country DASATINIB
Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin… Ended

2024-516435-27-00 Phase II 1 country BUSULFAN; FLUDARABINE PHOSPHATE; RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r… Ended

2024-518265-10-01 Phase I 1 country

Showing 1–9 of 9 trials

← All sponsors A–Z